| 去势抵抗性前列腺癌治疗药物开发 |
| |
| 引用本文： | 周向军,张杰. 去势抵抗性前列腺癌治疗药物开发[J]. 世界临床药物, 2014, 0(2): 74-79 |
| |
| 作者姓名： | 周向军 张杰 |
| |
| 作者单位： | 武汉大学人民医院泌尿外科;湖北理工学院附属黄石中心医院 |
| |
| 摘 要： | 至今能延长前列腺癌患者生命的有效治疗手段尚少,去势抵抗性前列腺癌（CRPC）是前列腺癌治疗的难点和重点之一。延长转移性CRPC患者生存期的治疗药物开发是目前关注的热点。本文系统综述抗雄激素药物、细胞毒药物和免疫抑制剂等几大类药物用于CRPC治疗的临床评价。
|
| 关 键 词： | 抗雄激素治疗 去势抵抗性前列腺癌（CRPC） 细胞毒药物治疗 免疫治疗 靶向治疗 |
Development of therapeutic drug for castration-resistant prostate cancer |
| |
| ZHOU Xiang-jun;ZHANG Jie. Development of therapeutic drug for castration-resistant prostate cancer[J]. WORLD CLINICAL DRUGS, 2014, 0(2): 74-79 |
| |
| Authors: | ZHOU Xiang-jun ZHANG Jie |
| |
| Affiliation: | ZHOU Xiang-jun;ZHANG Jie;Department of Urology, Renmin Hospital of Wuhan University;Huangshi Central Hospital, Hubei Polytechnic University; |
| |
| Abstract: | The treatment of castrate refractory-resistant cancer （CRPC）is still a challenge, as there are few effective therapies to lengthen life of patients. Many novel approaches with extended survival benefit are currently in development yielded promising results for patients. This review describes the therapeutic drug for CRPC. |
| |
| Keywords: | antiandrogen thearpy castrate-resistant prostate cancer （CRPC） cytotoxic therapy immunotherapy targeted therapy |
| 本文献已被 CNKI 维普 等数据库收录！ |
